デフォルト表紙
市場調査レポート
商品コード
1414642

トファシチニブの世界市場レポート 2024年

Tofacitinib Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
トファシチニブの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

トファシチニブの市場規模は近年急速に拡大しています。2023年の27億6,000万米ドルから2024年には31億2,000万米ドルに、CAGR13.0%で拡大します。過去の期間に見られた拡大は、臨床効果や臨床試験、規制当局の承認、対象疾患の罹患率の増加、医師の処方パターン、患者の受容などの要因によるものと考えられます。

トファシチニブの市場規模は今後数年で急成長が見込まれます。2028年の年間平均成長率(CAGR)は12.7%で、50億2,000万米ドルに成長します。予測期間中に予想される成長は適応症の拡大、市場参入への取り組み、競合情勢、リアルワールドエビデンス、患者中心のヘルスケアなどの要因に関連しています。予測期間中に予想される注目すべき動向としては、小児関節リウマチの治療への注力、皮膚科疾患におけるトファシチニブの探求、戦略的提携とパートナーシップ、治療ガイドラインにおけるリアルワールドエビデンスの統合、個別化医療アプローチへの注力などが挙げられます。

関節リウマチの有病率の増加が予想され、トファシチニブ市場の成長を促進すると予測されています。関節リウマチは、関節、内臓、手、足に影響を及ぼす自己免疫疾患であり、ヤヌスキナーゼ酵素を標的とするトファシチニブ医薬品が、その活性を阻害し、炎症を緩和すると見られています。例えば、2022年2月のNational Arthritis Data Workgroupのデータによると、米国では人口の22%を超える5250万人以上の成人が関節炎やその他のリウマチ性疾患の診断を受けていることが明らかになった。予測では、18歳以上の成人の関節炎患者は2030年までに6,700万人に達する可能性があります。このように、関節リウマチの有病率の増加は、トファシチニブ市場の成長に寄与しています。

炎症性腸疾患と闘う患者数の増加は、トファシチニブ市場の拡大を推進する構えです。クローン病や潰瘍性大腸炎などの慢性炎症性疾患を含む炎症性腸疾患(IBD)は、ヤヌスキナーゼ(JAK)酵素を阻害し、粘膜治癒を促進することによって症状を管理するトファシチニブの極めて重要な役割を示しています。クローン病・大腸炎カナダによる2023年6月の統計では、322,600人以上のカナダ人がIBDと共に生活しており、人口の約0.82%を占めていると推定されています。2035年までには、人口の約1.1%に相当する約47万人のカナダ人がIBDに罹患すると予測されています。このようなIBDの継続的な蔓延は、トファシチニブ市場の急成長に寄与しています。

2023年のトファシチニブ市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。トファシチニブ市場レポート対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のトファシチニブ市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗リウマチ薬
  • ヤヌスキナーゼ阻害剤
  • 免疫抑制剤
  • 世界のトファシチニブ市場、強さ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 5mg
  • 10mg
  • 11mg
  • 22mg
  • 世界のトファシチニブ市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • その他
  • 世界のトファシチニブ市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のトファシチニブ市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 潰瘍性大腸炎
  • 関節リウマチ
  • 乾癬
  • その他

第7章 地域および国の分析

  • 世界のトファシチニブ市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のトファシチニブ市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • トファシチニブ市場の競合情勢
  • トファシチニブ市場の企業プロファイル
    • Beacon Pharmaceuticals Limited
    • Pfizer Inc.
    • Globe Pharmaceuticals Ltd.
    • Drug International Limited
    • Dolphin Pharmaceuticals

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r12152

“Tofacitinib Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tofacitinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tofacitinib? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The tofacitinib market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Class: Antirheumatic; Janus Kinase Inhibitor; Immunosuppressant
  • 2) By Strength: 5mg; 10mg; 11mg; 22mg
  • 3) By Route Of Administration: Oral; Other Routes Of Administration
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • 5) By Application: Ulcerative Colitis; Rheumatoid Arthritis; Psoriasis; Other Applications
  • Companies Mentioned: Beacon Pharmaceuticals Limited; Pfizer Inc.; Globe Pharmaceuticals Ltd.; Drug International Limited; Dolphin Pharmaceuticals
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Tofacitinib is a medication employed in the treatment of ulcerative colitis and various rheumatic diseases, including rheumatoid arthritis and ankylosing spondylitis. It is specifically used for moderate to severely active ulcerative colitis cases when there is intolerance, inadequate response, or a loss of response to biological therapy or conventional treatments.

The primary drug classes to which tofacitinib belongs include antirheumatic, Janus kinase inhibitor, and immunosuppressant. Antirheumatic denotes any medication utilized for treating rheumatism. Tofacitinib is available in strengths of 5mg, 10mg, 11mg, and 22mg, with administration routes including oral and others. The distribution channels for this medication encompass hospital pharmacies, retail pharmacies, and online pharmacies. Tofacitinib is indicated for conditions such as ulcerative colitis, rheumatoid arthritis, psoriasis, and others.

The tofacitinib market research report is one of a series of new reports from The Business Research Company that provides tofacitinib market statistics, including tofacitinib industry global market size, regional shares, competitors with tofacitinib market share, detailed tofacitinib market segments, market trends, and opportunities, and any further data you may need to thrive in the tofacitinib industry. This tofacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tofacitinib market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.12 billion in 2024 at a compound annual growth rate (CAGR) of 13.0%. The expansion observed in the historical period can be ascribed to factors such as clinical efficacy and trials, regulatory approvals, an increase in the incidence of targeted conditions, physician prescribing patterns, and patient acceptance.

The tofacitinib market size is expected to see rapid growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The anticipated growth in the forecast period can be linked to factors such as expanded indications, market access initiatives, the competitive landscape, real-world evidence, and patient-centric healthcare. Noteworthy trends expected in the forecast period include a focus on the treatment of pediatric rheumatoid arthritis, exploration of tofacitinib in dermatological conditions, strategic collaborations and partnerships, integration of real-world evidence in treatment guidelines, and a focus on personalized medicine approaches.

The expected rise in the prevalence of rheumatoid arthritis is anticipated to fuel the growth of the tofacitinib market. Rheumatoid arthritis, an autoimmune and inflammatory disorder affecting joints, internal organs, hands, and feet, sees tofacitinib medications targeting Janus kinase enzymes, preventing their activity and mitigating inflammation. For example, data from the National Arthritis Data Workgroup in February 2022 revealed that over 52.5 million adults in the United States, exceeding 22% of the population, had received diagnoses of arthritis or other rheumatic diseases. Predictions indicate that adults aged 18 and above with arthritis could reach 67 million by 2030. Thus, the increasing prevalence of rheumatoid arthritis contributes to the growth of the tofacitinib market.

The growing number of patients grappling with inflammatory bowel disease is poised to propel the tofacitinib market's expansion. Inflammatory Bowel Disease (IBD), encompassing chronic inflammatory conditions such as Crohn's disease and ulcerative colitis, witnesses tofacitinib's pivotal role in managing symptoms by inhibiting Janus kinase (JAK) enzymes and promoting mucosal healing. Statistics from Crohn's and Colitis Canada in June 2023 estimated that over 322,600 Canadians were living with IBD, accounting for about 0.82% of the population. Projections suggest that by 2035, around 470,000 Canadians, or approximately 1.1% of the population, may be living with IBD. This ongoing prevalence of IBD contributes to the escalating growth of the tofacitinib market.

Product innovation stands out as a prominent trend gaining momentum in the tofacitinib market. Leading companies in the tofacitinib market are actively engaged in developing innovative products to maintain their market position. An illustrative example is Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, which announced in December 2021 that the U.S. Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for tofacitinib-based medications XELJANZ and XELJANZ XR. XELJANZ marks the first and only Janus kinase (JAK) inhibitor authorized in the United States for treating five immuno-inflammatory diseases. The approval of XELJANZ for ankylosing spondylitis (AS) was based on a Phase 3 multicenter, randomized, double-masked, placebo-controlled study that assessed the safety and efficacy of tofacitinib.

Major companies in the tofacitinib market are placing increased emphasis on introducing topical tofacitinib medications to gain a competitive advantage. Topical tofacitinib refers to a formulation designed for topical application on the skin. A noteworthy instance is Intas Pharmaceuticals, an India-based pharmaceutical company, which launched Tofacitinib Topical (JAKi) in June 2023 for treating mild to moderate atopic dermatitis (AD) in India. This marks the first approval of a JAK inhibitor for AD in India. The successful Phase III clinical study of TOFATAS (Tofacitinib Ointment 2% w/w) demonstrated notable safety and efficacy in atopic dermatitis patients. The introduction of TOFATAS is aimed at providing renewed hope to AD patients, addressing an unmet need for approved topical JAK inhibitors in India.

In March 2022, Pfizer Inc. furthered its market position through the acquisition of Arena Pharmaceuticals for $6.7 billion. This strategic move enhances Pfizer Inc.'s portfolio by adding potential drugs for gastroenterology, dermatology, and cardiology, including a potential follow-up to the inflammatory disorder drug Xeljanz (tofacitinib). Arena Pharmaceuticals, a US-based biopharmaceutical company, brings small-molecule medications into Pfizer Inc.'s pipeline, expanding the potential clinical applications across various therapeutic fields.

Major companies operating in the tofacitinib market report are Beacon Pharmaceuticals Limited, Pfizer Inc., Globe Pharmaceuticals Ltd., Drug International Limited, Dolphin Pharmaceuticals, Lancer Therapeutics, Glenmark Pharmaceuticals LTD., Sun Pharmaceutical Industries Ltd., Shandong Octagon Chemicals Limited, Zydus Lifesciences Ltd., Esteve Pharmaceuticals SA, Unichem Laboratories, Beijing Mesochem Technology Co. Ltd., Aprazer Healthcare Pvt Ltd., Apino Pharma Co Ltd., Delta Pharma Limited, Mediconlife, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Jubilant Life Sciences, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited

North America was the largest region in the tofacitinib market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the tofacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The tofacitinib market consists of sales of Xeljanz and Xeljanz XR. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Tofacitinib Market Characteristics

3. Tofacitinib Market Trends And Strategies

4. Tofacitinib Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Tofacitinib Market Size and Growth

  • 5.1. Global Tofacitinib Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Tofacitinib Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Tofacitinib Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Tofacitinib Market Segmentation

  • 6.1. Global Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antirheumatic
  • Janus Kinase Inhibitor
  • Immunosuppressant
  • 6.2. Global Tofacitinib Market, Segmentation By Strength, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 5mg
  • 10mg
  • 11mg
  • 22mg
  • 6.3. Global Tofacitinib Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Other Routes Of Administration
  • 6.4. Global Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • 6.5. Global Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ulcerative Colitis
  • Rheumatoid Arthritis
  • Psoriasis
  • Other Applications

7. Tofacitinib Market Regional And Country Analysis

  • 7.1. Global Tofacitinib Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Tofacitinib Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Tofacitinib Market

  • 8.1. Asia-Pacific Tofacitinib Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Tofacitinib Market

  • 9.1. China Tofacitinib Market Overview
  • 9.2. China Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Tofacitinib Market

  • 10.1. India Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Tofacitinib Market

  • 11.1. Japan Tofacitinib Market Overview
  • 11.2. Japan Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Tofacitinib Market

  • 12.1. Australia Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Tofacitinib Market

  • 13.1. Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Tofacitinib Market

  • 14.1. South Korea Tofacitinib Market Overview
  • 14.2. South Korea Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Tofacitinib Market

  • 15.1. Western Europe Tofacitinib Market Overview
  • 15.2. Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Tofacitinib Market

  • 16.1. UK Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Tofacitinib Market

  • 17.1. Germany Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Tofacitinib Market

  • 18.1. France Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Tofacitinib Market

  • 19.1. Italy Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Tofacitinib Market

  • 20.1. Spain Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Tofacitinib Market

  • 21.1. Eastern Europe Tofacitinib Market Overview
  • 21.2. Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Tofacitinib Market

  • 22.1. Russia Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Tofacitinib Market

  • 23.1. North America Tofacitinib Market Overview
  • 23.2. North America Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Tofacitinib Market

  • 24.1. USA Tofacitinib Market Overview
  • 24.2. USA Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Tofacitinib Market

  • 25.1. Canada Tofacitinib Market Overview
  • 25.2. Canada Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Tofacitinib Market

  • 26.1. South America Tofacitinib Market Overview
  • 26.2. South America Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Tofacitinib Market

  • 27.1. Brazil Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Tofacitinib Market

  • 28.1. Middle East Tofacitinib Market Overview
  • 28.2. Middle East Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Tofacitinib Market

  • 29.1. Africa Tofacitinib Market Overview
  • 29.2. Africa Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Tofacitinib Market Competitive Landscape And Company Profiles

  • 30.1. Tofacitinib Market Competitive Landscape
  • 30.2. Tofacitinib Market Company Profiles
    • 30.2.1. Beacon Pharmaceuticals Limited
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Globe Pharmaceuticals Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Drug International Limited
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Dolphin Pharmaceuticals
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Tofacitinib Market Competitive Benchmarking

32. Global Tofacitinib Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Tofacitinib Market

34. Tofacitinib Market Future Outlook and Potential Analysis

  • 34.1 Tofacitinib Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Tofacitinib Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Tofacitinib Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer